patented technology to grow and expand adult Stem Cells
Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place
3-2-16, Pluristem's Radiation Antidote Bests Blockbuster Drug Neupogen
PLX-R18 Heals 100% of Population Exposed To Lethal Radiation through Nuclear Accident or Attack; Ready To Supply U.S. Government.
2-2-15, Significant New Finding From Its Phase I/II Muscle Injury Trial - Excellent Safety Profile for Cells at Twelve Months.
Data showed the magnitude of improvement in muscle force of 40 times larger in patients treated with PLX-PAD.
3-6-14, US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process.
Pluristem Fortifies Leadership Position in Cell Therapy Following Multiple Regulatory Approvals of Its New PLX Cell Mass Production Facility.
FAQs Regarding Pluristem's Stem Cell Process.
What is the uniqueness of Pluristem’s technology? And May Others.
Scientific Advisory Board
Edwin M Horwitz, MD, PhD, / Brian Annex, MD, / Prof. Arnon Nagler, / Jacob Michael Rowe, M.D., F.A.C.P., / Prof. Ron Gonen, M.D, / Dr. Avinoam Kadouri, /& Dr. Abraham Treves.
Business Strategy Advisory Board / Must See, Impressive Credentials
Frank C. Carlucci & Philip S. Schein, M.D.
2-11-09, Pluristem Appoints Dr. Frida Grynspan to Vice President of R&D.
<em><span style="font-size: 9pt; font-family: Arial; color: green;">1-27-09, Pluristem Plans to Initiate Dose Ranging Clinical Trials at the Charité and Franziskus-Krankenhaus hospitals in Germany. </span></em>